Travere Therapeutics
TVTX
171 hedge funds and large institutions have $1.54B invested in Travere Therapeutics in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 67 reducing their positions, and 19 closing their positions.
117% more call options, than puts
Call options by funds: $4.14M | Put options by funds: $1.91M
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
1% more funds holding
Funds holding: 169 → 171 (+2)
0.59% less ownership
Funds ownership: 110.04% → 109.46% (-0.59%)
10% less capital invested
Capital invested by funds: $1.7B → $1.54B (-$162M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
18% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$19.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$16.1M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$14.7M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$32.1M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$18.8M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$16.8M |
| 4 |
Millennium Management
New York
|
-$16.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13M |
TVTX Hedge Fund Activity: Q2 2022 in Review
171 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2022, worth a combined $1.54B — down 9.5% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TVTX positions and 19 closed out — a net gain of 5 holders — while 55 added to existing stakes and 67 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $19.4M. The largest seller was Perceptive Advisors, cutting an estimated $32.1M.
- 171 institutional investors held Travere Therapeutics (TVTX) as of Q2 2022, up from 169 in Q1 2022.
- Funds reported $1.54B of Travere Therapeutics stock for Q2 2022, down 9.5% quarter-over-quarter.
- 24 funds opened new Travere Therapeutics positions in Q2 2022 and 19 closed out, a net change of +5 holders.
- The largest Travere Therapeutics buyer in Q2 2022 was OrbiMed, an estimated $19.4M added.
- The largest Travere Therapeutics seller in Q2 2022 was Perceptive Advisors, an estimated $32.1M sold.
Based on aggregated 13F filings for Q2 2022.